A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU) - Full Text View

Sponsored by:	Diamyd Therapeutics AB
Information provided by:	Diamyd Therapeutics AB
ClinicalTrials.gov Identifier:	NCT00723411

Purpose

The purpose of this study is to determine whether Diamyd (rhGAD65 formulated in alum) is effective in preserving the body's own insulin producing capacity in patients recently diagnosed with type 1 diabetes.

Condition	Intervention	Phase
Type 1 Diabetes Mellitus	Drug: rhGAD65 Drug: Placebo	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	A Phase III, 3-Arm, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Impact of Diamyd on the Progression of Diabetes in Patients Newly Diagnosed With Type 1 Diabetes Mellitus (EU)

Resource links provided by NLM:

MedlinePlus related topics: Diabetes Diabetes Type 1

Drug Information available for: Aluminum sulfate Alum, Potassium

U.S. FDA Resources

Further study details as provided by Diamyd Therapeutics AB:

Primary Outcome Measures:

Meal stimulated C-peptide (area under the curve) [ Time Frame: 15 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

HbA1c [ Time Frame: 15 months ] [ Designated as safety issue: No ]
Insulin Dose [ Time Frame: 15 months ] [ Designated as safety issue: No ]

Estimated Enrollment:	320
Study Start Date:	July 2008
Estimated Study Completion Date:	October 2011
Estimated Primary Completion Date:	July 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
A: Active Comparator This arm will receive 2 subcutaneous injections with 20 µg Diamyd on Days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on Days 90 and 270.	Drug: rhGAD65 Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
B: Active Comparator This arm will receive 2 subcutaneous injections with 20 µg Diamyd on Days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on Days 90 and 270.	Drug: rhGAD65 Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
C: Placebo Comparator This arm will receive 4 injections of placebo, 1 each on Days 1, 30, 90, and 270.	Drug: Placebo Placebo injected subcutaneously at days 1, 30, 90 and 270

Eligibility

Ages Eligible for Study:	10 Years to 20 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Main Inclusion Criteria:

Male and female patients between 10 and 20 years of age
Insulin dependent type 1 diabetes mellitus diagnosed within the previous 3 months at time of screening
Fasting C-peptide level at time of screening above 0.1 nmol/L
Elevated GAD65 antibodies (GADA) at time of screening

Main Exclusion Criteria:

Treatment with immunosuppressants or any anti-diabetic medications other than insulin
A history of certain diseases or conditions (e.g. anemia, HIV, hepatitis, epilepsy, head trauma, neurological diseases or cerebrovascular accident, alcohol or drug abuse etc)
Treatment with any vaccine within 1 month prior to planned first Diamyd dose or planned treatment with vaccine up to 2 months after the last injection with Diamyd, excluding the influenza vaccine
Participation in other clinical trials with a new chemical entity within the previous 3 months
Pregnancy or planned pregnancy within 1 year after the last Diamyd dose
Presence of associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00723411

Contacts

Contact: Ulf Parkhede

+46-8-4407622

ulf.parkhede@trialformsupport.com

Show 72 Study Locations

Sponsors and Collaborators

Diamyd Therapeutics AB

Investigators

Principal Investigator:

Johnny Ludvigsson, MD, PhD

Linköping University, Sweden

More Information

No publications provided

Responsible Party:	Diamyd Therapeutics AB ( Managing Director )
Study ID Numbers:	D/P3/07/4
Study First Received:	July 24, 2008
Last Updated:	August 14, 2009
ClinicalTrials.gov Identifier:	NCT00723411 History of Changes
Health Authority:	Sweden: Medical Products Agency; Sweden: Regional Ethical Review Board; Finland: National Agency for Medicines; Finland: Ethics Committee; Slovenia: Agency for Medicinal Products - Ministry of Health; Slovenia: Ethics Committee; Spain: Spanish Agency of Medicines; Spain: Comité Ético de Investigación Clínica; Netherlands: Medical Ethics Review Committee (METC); Netherlands: The Central Committee on Research Involving Human Subjects (CCMO); Italy: The Italian Medicines Agency; Italy: Ethics Committee; United Kingdom: Medicines and Healthcare Products Regulatory Agency; United Kingdom: Research Ethics Committee; Germany: Federal Institute for Drugs and Medical Devices; Germany: Ethics Commission; France: Agence francaise de sécurité sanitaire des produits de santé, (afssaps); France: Institutional Ethical Committee

Keywords provided by Diamyd Therapeutics AB:

Diabetes
Juvenile Diabetes
Diabetes type 1
Autoimmune Diabetes
Insulin dependent Diabetes
Type 1 diabetes

Type 1 diabetes mellitus
Diamyd
rhGAD65
GAD
GAD-alum

Study placed in the following topic categories:

Aluminum sulfate
Autoimmune Diseases
Metabolic Diseases
Diabetes Mellitus, Type 1
Disease Progression
Diabetes Mellitus

Endocrine System Diseases
Diabetes Mellitus Type 1
Endocrinopathy
Glucose Metabolism Disorders
Metabolic Disorder
Insulin

Additional relevant MeSH terms:

Autoimmune Diseases
Metabolic Diseases
Immune System Diseases
Diabetes Mellitus, Type 1

Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders

ClinicalTrials.gov processed this record on September 11, 2009